Stockwinners Market Radar for June 29, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:16 EDT Cathie Wood's ARK Investment bought 1.57M shares of Ginkgo Bioworks today

20:03 EDT Tesla exec sells $2.62M in common stock - In a regulatory filing, Tesla disclosed that its Powertrain SVP Andrew Baglino sold 3.5K shares of common stock on June 27th in a total transaction size of $2.62M as part of option exercize.

18:52 EDT Great Panther Mining enters into agreement to sell four mine projects in Mexico - Great Panther Mining has entered into a Share Purchase Agreement with Guanajuato Silver Company to sell 100% of the company's Mexican subsidiary Minera Mexicana El Rosario - MMR -, which holds the Guanajuato Mine Complex - GMC -, the Topia mine, and the El Horcon and Santa Rosa projects, all located in Mexico. GSilver will purchase MMR for a total upfront consideration of $14.7M plus up to $2M in additional payments, payable as follows: $8M cash payable on closing; a total of 25,787,200 common shares of GSilver valued at approximately $6.7M based on current trading prices; $500K upon producing 2.5 million ounces of silver from the GMC and Topia; $750K upon the price of silver closing at or above $27.50 per ounce over a 30-day period in the two years following the agreement; $750K upon the price of silver closing at or above $30.00 per ounce over a 30-day period in the two years following the agreement. In conjunction with closing, MMR will repay the balance outstanding of the Samsung lead concentrate prepayment facility, and accordingly Samsung will release the pledge of MMR shares associated with this facility. Closing of the agreement, expected in Q3, is subject to satisfaction of certain conditions including receipt of all requisite third-party and regulatory approvals.

18:18 EDT DOJ sues to block Booz Allen's proposed acquisition of EverWatch - The U.S. Department of Justice filed a civil antitrust lawsuit to block Booz Allen Hamilton Holding Corporation's proposed acquisition of EverWatch Corp., a subsidiary of EC Defense Holdings LLC. The complaint, filed in the U.S. District Court for the District of Maryland, alleges that the merger agreement threatens imminent competition for a government contract to provide operational modeling and simulation services to the National Security Agency. Unless enjoined, the transaction would eliminate competition for this defense contract, leaving NSA to face a monopoly bidder. "Booz Allen's agreement to acquire EverWatch imperils competition in a market that is vital to our national security," said Assistant Attorney General Jonathan Kanter of the Justice Department's Antitrust Division. "Both the acquisition agreement and the underlying transaction violate federal antitrust law."

18:09 EDT Snow Lake Resources receives shareholder meeting requisition - Snow Lake Resources Ltd., d/b/a Snow Lake Lithium Ltd., announced that it has been provided with a shareholder meeting requisition notice dated June 8, 2022 from a number of registered shareholders holding, collectively as a group, approximately 5.4%of the issued and outstanding shares in the company. The group includes individuals and entities associated with Avrohom Mordechai Kimelman, of St Kilda East, Victoria, Australia, a former director of the company and former CEO and Director of Quantum Resources, which later changed its name to Nova Minerals Limited. The Requisition requests that the directors of the company call a meeting of the shareholders of the company for the purpose of (a) removing all of the directors of the company; (b) fixing the number of directors at six for the ensuing year; and (c) electing six nominee directors of the Kimelman Group. The company has reviewed the Requisition with its professional advisors and announces today that its Board of Directors has called a special meeting of shareholders to be held in conjunction with its annual meeting of shareholders on or about the 15th day of December, 2022 to consider the matters, among other business, raised by the Requisition. Shareholders will receive formal notice of the meeting and an information circular in sufficient time to consider all matters. In the meantime, there is currently no need for shareholders to take any action.

17:17 EDT Rocket Lab's Lunar Photon spacecraft completes third orbit raising maneuver - Rocket Lab "announced its Lunar Photon spacecraft has successfully completed the third of seven planned orbit raising maneuvers, bringing the CAPSTONE spacecraft closer to the Moon. The orbit raising maneuvers come after Rocket Lab successfully launched CAPSTONE to an initial parking orbit on June 28 with an Electron rocket from Launch Complex 1 in New Zealand. With Electron's role in the mission now complete, Lunar Photon has taken over the reins, providing power, communications and in-space transportation to CAPSTONE for the next five-day mission phase."

16:48 EDT Xerox: CEO John Visentin has passed away, Steve Bandrowczak named Interim CEO - Xerox Vice Chairman and CEO John Visentin, unexpectedly passed away yesterday due to complications from an ongoing illness. Steve Bandrowczak, Xerox's President and COO since 2018, will serve as Interim CEO. Steve currently develops and executes the global operations strategy for Xerox, the company's business support functions, including business strategy, product and service delivery and information technology, as well as the company's newly formed Software and Innovation businesses.

16:47 EDT Pfizer/BioNTech enter new $3.2B deal with U.S. government on COVID vaccines - Pfizer (PFE) and BioNTech (BNTX) "announced a new vaccine supply agreement with the U.S. government to support the continued fight against COVID-19. Under the agreement, the U.S. government will receive 105 million doses. This may include adult Omicron-adapted COVID-19 vaccines, subject to authorization from the U.S. Food and Drug Administration. The doses are planned to be delivered as soon as late summer 2022 and continue into the fourth quarter of this year. The U.S. government will pay the companies $3.2 billion upon receipt of the first 105 million doses. Under this agreement, the U.S. government also has the option to purchase up to 195 million additional doses, bringing the total number of potential doses to 300 million."

16:44 EDT MillerKnoll jumps 6% to $29.70 after Q4 results beat estimates

16:35 EDT Angion Biomedica Corporation trading resumes

16:30 EDT Canadian Pacific announces ratification of three new labor agreements - Canadian Pacific announced three collective bargaining agreements have been ratified by employees of CP's Dakota, Minnesota & Eastern South; Central Maine & Quebec U.S. and Central Maine & Quebec Canada subsidiaries. The agreements, reached on CP properties in Maine, the U.S. Midwest and parts of Quebec, provide higher hourly wages for all employees. They affect a total of approximately 430 employees represented by United Steel Workers Local 1976 on the CMQ Canada, SMART Transportation Division representing all employees on the CMQ U.S. and the Brotherhood of Locomotive Engineers and Trainmen representing all train and engine employees on the DM&E South. "CP welcomes the ratification of these three recently negotiated agreements that bring wage increases to hundreds of our dedicated employees," said Mark Redd, CP Executive Vice-President Operations. "We continue to work productively with all of our union partners to achieve long-term agreements that meet the needs of CP's growing business and our industry-leading railroaders." Major CP crew bases that fall under the agreements include Ottumwa, Davenport, Marquette and Mason City, Iowa; Kansas City, Mo.; Savanna, Ill.; Brownville Junction, Maine; and Farnham, Que. CP is hiring for various positions at all of these locations in 2022, with immediate openings.

16:27 EDT Scorpio Tankers announces purchase of shares by President Robert Bugbee - Scorpio Tankers announces that the President of the company, Robert Bugbee, has purchased 50,000 common shares of the company in the open market at an average price of $34.70 per share.

16:24 EDT Adagene announces $10M share repurchase program - Adagene announced that its board of directors has authorized a share repurchase program under which, Adagene may repurchase up to $10M of its ordinary shares in the form of American depositary shares, subject to the relevant rules under the Securities Exchange Act of 1934, as amended and the company's insider trading policy.

16:20 EDT Mercury Systems gets $10M contract award for airborne radio upgrade - Mercury Systems announced it received a $10M award to provide an innovative pilot controller interface for a leading prime contractor's airborne radio modernization program. The radio system, built specifically for missions that depend on beyond line-of-sight range, requires the space efficient, affordable and modular communications connection that Mercury's processing solution delivers. The award was received in the Company's fiscal 2022 fourth quarter and is expected to be delivered over the next several years.

16:18 EDT Regional Management expands operations to Indiana - Regional Management Corp. announced that it has expanded its operations to Indiana, its 15th U.S. state, with the opening of its first branch in Merrillville. The opening further expands Regional Management's de novo footprint within the Midwestern U.S. "We are very pleased to bring to Indiana our suite of affordable financial solutions for hard-working Hoosiers," said Robert W. Beck, President and Chief Executive Officer of Regional Management Corp. "Our omni-channel operating model will enable consumers throughout Indiana to access our premier lending solutions at their convenience, while allowing us to reach additional high-quality customers in new markets. Our geographic expansion strategy continues to position us well to grow our market share in a controlled manner and to continue delivering sustainable long-term value to our shareholders."

16:17 EDT Diversified Healthcare Trust sells 10% equity interest for $108M - Diversified Healthcare "announced that it has sold an additional 10% equity interest in the two building life science complex located at 11 Fan Pier and 50 Northern Avenue in Boston, MA. DHC sold the interest to an existing joint venture partner for a purchase price of approximately $108 million. The purchasing partner now owns a 45% interest in the joint venture, another partner continues to own a 45% equity interest, and DHC owns the remaining 10% equity interest. The purchase price for the 10% equity interest is based on a property valuation of $1.7 billion, less the $620 million of existing secured debt on the property."

16:15 EDT Corcept Therapeutics initiates ROSELLA trial - Corcept Therapeutics announced that it has initiated ROSELLA, a pivotal Phase 3 trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer.

16:12 EDT RH falls 5% to $225 after cutting FY22 revenue guidance

16:09 EDT MillerKnoll re-establishing share repurchase program - The company said, "At the end of the fourth quarter, our liquidity position reflected cash on hand and availability on our revolving credit facility totaling $526.9 million. In the fourth quarter of fiscal 2020, we temporarily suspended open market share repurchase activity as part of managing cash flows associated with uncertainty caused by the pandemic. Going forward, we are re-establishing our open market share repurchase program under our existing share repurchase authorization and may repurchase shares from time to time based on management's evaluation of market conditions, share price and other factors."

16:08 EDT MillerKnoll reports Q4 adjusted gross margin 34.8% vs. 38.1% a year ago

16:07 EDT SGH to acquire Stratus Technologies - SGH announced its entry into a definitive agreement to acquire Stratus Technologies, a player in high-availability, fault-tolerant systems and software in the data center and at the Edge. "Today, we are taking another important step in our transformation with the announcement of our entry into a definitive agreement to acquire Stratus Technologies, a global leader in simplified, protected, and autonomous computing solutions in the data center and at the Edge," continued Mr. Adams. "Following the close of the transaction, expected to occur in the second half of calendar 2022, Stratus will operate as part of SGH's Intelligent Platform Solutions (IPS) business line. We are excited to welcome the Stratus team to SGH as we continue to expand our capabilities with their high-availability, fault-tolerant computing platforms, software and services."

16:01 EDT Angion Biomedica Corporation trading halted, news pending

15:33 EDT FedEx sees adjusted free cash flow 'north of $4B' in 2023 - Asked earlier during the company's investor day meeting about free cash flow projections, executives from FedEx stated, according to a transcript of the event, that "we have $3.5 billion of free cash flow, adjusted free cash flow in 2022. We'll be north of that - north of $4 billion in 2023. And obviously that number grows with the projections there to get to the numbers we have beyond that." Shares of FedEx remain down $5.78, or about 2%, at $234.31 near 3:30 PM following the conclusion of the company's investor meeting earlier this afternoon.

14:35 EDT GD NASSCO awarded $600M for U.S. Navy contract modifications - General Dynamics NASSCO, a subsidiary of General Dynamics, announced that it was awarded $600M in U.S. Navy contract modifications for long-lead-time material to support construction of the seventh and eighth ships in the John Lewis-class fleet oiler program, as well as the sixth ship in the Expeditionary Sea Base program. The contract modifications for long-lead-time material provide $500M for T-AO 211 and 212, and $100M for ESB 8. Construction is scheduled to begin in the third quarter of 2023 and continue into 2027, providing the opportunity to sustain and grow the workforce along San Diego's working waterfront. NASSCO's unique location in San Diego Bay provides shipbuilders and skilled tradespeople with access to the nation's leading maritime support businesses, and highly trained employees allow NASSCO to build and repair Navy ships in an efficient manner.

13:51 EDT Equinor sells 51% interest in North Platte project to Shell - Equinor (EQNR) said it has agreed to sell to Shell (SHEL) 51% of its interest in the North Platte deep water development project in the U.S. Gulf of Mexico. Equinor will retain 49% interest in the project, and Shell will become the new operator of the field. Equinor and Shell have agreed to rename the North Platte development to the Sparta development. Sparta straddles four blocks of the Garden Banks area, 275 kilometers off the coast of Louisiana in approximately 1,300 meters of water depth. The transaction is subject to customary conditions and authority approval.

13:29 EDT Hoth Therapeutics says 180 day closing bid rule extension granted by Nasdaq - Hoth Therapeutics announced that the company received confirmation from the Listing Qualification Department of The NASDAQ Capital Market notifying the company that Nasdaq has granted the company an additional 180-day compliance period, or until December 26, to regain compliance with Nasdaq's minimum $1.00 closing bid price per share requirement.

12:27 EDT Elbit Systems awarded roughly $220M airborne precision munition contract - Elbit Systems announced that it was awarded an approximately $220M contract to supply precision guidance kits for airborne munitions to a country in Asia-Pacific. The contract will be performed over a period of 15 months. Under the contract, Elbit Systems will supply the Lizard precision guidance kit for general purpose airborne warheads. The Lizard is a laser-based precision guidance kit enabling general purpose airborne warheads, of both Western and Eastern versions, to engage targets, including fast moving ones, with high accuracy. Bezhalel Machlis, Elbit Systems President & CEO, commented: "There is an increase in the demand for our precision fire capabilities as high accuracy has become an operational imperative across all domain of operations. Armed forces around the globe are requiring solutions that enable efficient conversion of ammunition stockpiles into a capability that is relevant in modern warfare, especially in light of lessons learned from recent military conflicts."

12:04 EDT Exicure implementing one-for-30 reverse stock split - Exicure announced that, following the implementation of a one-for-thirty reverse stock split at 5:00 p.m. EDT today, the company's common stock will begin trading on a split-adjusted basis on Nasdaq effective with the open of business tomorrow, Thursday, June 30. The company's common stock will continue to trade under the ticker symbol "XCUR". The company is implementing the reverse stock split in an effort to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share. As a result of the reverse stock split, every thirty pre-split shares of common stock outstanding will be automatically combined and converted into one issued and outstanding share of common stock, without any change in the par value per share. No fractional shares of the company's common stock will be issued to any stockholders in connection with the reverse stock split. Holders of record will receive a cash payment in lieu of fractional shares. In any event, should the company evidence compliance with the Bid Price Requirement for the requisite minimum ten-consecutive business day period prior to or following the hearing, the company will request that Nasdaq issue a compliance determination, in which case the listing matter will be closed.

12:00 EDT Revlon falls -19.2% - Revlon is down -19.2%, or -$1.06 to $4.47.

12:00 EDT Eve Holding rises 8.1% - Eve Holding is up 8.1%, or 44c to $5.89.

12:00 EDT Stride rises 10.7% - Stride is up 10.7%, or $4.03 to $41.80.

11:07 EDT AbCellera says Lilly to supply U.S. with added 150,000 bebtelovimab doses - AbCellera (ABCL) announced that Eli Lilly and Company (LLY) has entered into a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab, the second antibody developed through AbCellera's collaboration with Lilly, for approximately $275M. "The existing U.S. government supply of bebtelovimab, including the new purchase, is expected to meet present demand through late August 2022. Delivery of doses will begin immediately and complete no later than August 5, 2022. An option for an additional 350,000 doses to be exercised no later than September 14, 2022, will remain in the agreement... Bebtelovimab continues to maintain neutralization activity against the most common, and fastest growing, Omicron variants (BA.2.12.1 and BA.4/BA.5) in the United States, in addition to all known variants of interest and concern," AbCellera stated.

10:54 EDT JetBlue tells crew Spirit will 'need to reconsider' if holders vote down deal - JetBlue (JBLU) made public a letter shared with its Crewmembers from CEO Robin Hayes in advance of the Spirit (SAVE) special meeting on June 30, which states in part: "The Spirit special shareholder meeting is set for tomorrow, and many of you are wondering if we will reach a conclusion to all of this. If Spirit shareholders vote down the Frontier proposal, the Spirit board will need to reconsider the very clear benefits of our offer... Customers would win with a bigger JetBlue - the unique combination of our beloved brand, award-winning service, and everyday low fares force the high-fare legacies to compete. A Frontier-Spirit tie-up is a missed opportunity for increased competition and denies Customers an attractive alternative to bare-bones travel. In addition, folding Spirit into JetBlue would turbocharge our expansion. We would get more aircraft, more gates and airport space, more flights, and more Crewmembers - making our brand and products more relevant to more Customers across the country. This growth would be great for JetBlue Crewmembers too as a bigger JetBlue offers more career opportunities. From the beginning, the Spirit board has not run a fair process and they've said many things about us that are blatantly false. They have deep ties to Frontier's owner, and they have always believed a Frontier-Spirit merger was inevitable. Some Spirit shareholders have indicated to us that they have doubts about the Spirit board too, and this gives us confidence that they will vote down the Frontier merger. Whatever the outcome tomorrow, I'm proud that our team went after this opportunity and put forward our best effort."

10:19 EDT General Dynamics Land Systems announces LRIP award valued at $1.14B - General Dynamics Land Systems, a business unit of General Dynamics, announced that its Mobile Protected Firepower, or MPF, offering has been chosen by the U.S. Army through a competitive process to provide enhanced firepower for Infantry Brigade Combat Teams, or IBCTs. The Low Rate Initial Production, or LRIP, award is valued at $1.14B. "We are honored that the Army has chosen our offering for this important program. Our team worked tirelessly to deliver our prototypes in time to support the Army's evaluation plan, and we incorporated Soldier feedback into the final design," said Gordon Stein, General Dynamics Land Systems vice president and general manager for U.S. operations.

10:00 EDT Carnival plc falls -12.8% - Carnival plc is down -12.8%, or -$1.20 to $8.21.

10:00 EDT Aspen Aerogels falls -40.6% - Aspen Aerogels is down -40.6%, or -$5.97 to $8.74.

10:00 EDT Direxion Daily Semiconductor Bear 3X Shares rises 8.9% - Direxion Daily Semiconductor Bear 3X Shares is up 8.9%, or $5.31 to $64.97.

09:57 EDT SG Blocks announces SG Echo released from design phase - SG Blocks announced that SG Echo, SG Blocks' owned and operated manufacturing facility which specializes in the design and construction of permanent modular and temporary modular buildings, has been released from its design phase for its agreement with a leading contractor for a United States Military SCIF. The project is now moving to the production phase. The contract, which is for $767,682 commenced in October of 2021 and aims for completion in October of 2022. SG Echo is building the secured pre-fabricated facility for a government entity in-house, with its factory featuring approximately 70,000 square feet of modular manufacturing space.

09:47 EDT Carnival plc falls -9.3% - Carnival plc is down -9.3%, or -88c to $8.54.

09:47 EDT Ormat Technologies rises 8.4% - Ormat Technologies is up 8.4%, or $6.07 to $78.36.

09:47 EDT Stride rises 10.3% - Stride is up 10.3%, or $3.89 to $41.66.

09:42 EDT BNOX Stock trading resumes

09:37 EDT Icosavax trading halted, volatility trading pause

09:28 EDT Luokung Technology subsidiary to supply autonomous driving data for Volvo - Luokung Technology's operating affiliate eMapGo Technology, a provider of navigation and electronic map services in China, has signed an agreement to continue to provide autonomous driving data services for Zenseact after EMG obtained the Phase I project in September of 2021. Zenseact is a wholly owned subsidiary of Volvo Cars, the automotive division of the Swedish multinational manufacturing company, focusing on the development of autonomous driving and active safety software together with its lead customer Volvo Cars.

09:18 EDT CEA Industries signs letter of engagement with Merida Capital Holdings - CEA Industries announced it has entered into an agreement with Merida Capital Holdings in which Merida agrees to use the Company as its sole provider of certain products and services for Merida's indoor cultivation facilities. "Our subsidiary, Surna Cultivation Technologies, has been and is working with Merida on several projects, and we are excited to formalize and extend our relationship for future opportunities," stated Tony McDonald, Chairman and CEO of CEA Industries. Surna's products and services include but are not limited to full-service licensed architectural and mechanical, electrical, and plumbing engineering services, carefully curated HVACD equipment, proprietary controls systems, air sanitization, lighting, and benching and racking products.

09:16 EDT BriaCell enters research agreement to identify targets for cancer treatment - BriaCell Therapeutics announced a research collaboration agreement with Harvard Medical School in support of a project led by Joan Brugge, PhD, a faculty member. The project aims to discover new targets that may lead to the development of novel anti-cancer treatments. The research collaboration will focus on the discovery and development of novel targets to enhance tumor cell responsiveness to chemotherapy and immunotherapies in specific cancers including lung, head and neck, cervical, and bladder cancers. "We are grateful for the opportunity to work with Prof. Brugge and her expert team at Harvard Medical School to advance discovery in oncology," stated Dr. Miguel Lopez-Lago, BriaCell's Chief Scientific Officer. "We are hopeful that insights from this effort may potentially inform BriaCell's future R&D aims in developing novel anti-cancer drugs. This research collaboration is in line with our overall strategy of developing safe and effective treatments for cancer patients with large unmet medical needs."

09:12 EDT Urban-Gro signs over $10M in design-build, construction management contracts - urban-gro announced that it has signed and began execution of seven design-build and construction management-related contracts since the closing of its most recent acquisition, Emerald C.M., just over 90-days ago. These contracts, which are incremental to backlog, are signed with multi-billion dollar enterprise clients. Bradley Nattrass, Chairman and CEO, commented, "We are thrilled to announce these new contracts with several marquee companies, each of which are global leaders within their respective industries. Our ability to penetrate these markets and service a set of high-profile customers speaks to our full suite of capabilities that we've built through leveraging our balance sheet and making accretive and synergistic acquisitions. Diversification of our offerings beyond CEA is not only a key area of organic growth for us, but also fosters a more efficient operating model by giving us the flexibility to allocate design resources based on demand variances in each market segment. We look forward to continuing to capitalize on opportunities in adjacent markets as our Company evolves as a fully integrated turnkey design-build EPC player."

09:07 EDT Ocuphire Pharma granted new US patent for APX3330 - Ocuphire Pharma announced that the United States Patent and Trademark Office, USPTO, has issued a new patent extending expiry and broadening coverage of the company's late-stage oral product candidate, APX3330. In addition, a new publication supporting the novel mechanism of action inhibiting NFkB and the inflammation pathway for APX3330 and the APX pipeline candidates has been published in a peer-reviewed journal. "We are pleased to announce the issuance of a new U.S. patent that further strengthens our patent estate for APX3330," said Mina Sooch, MBA, Founder and CEO of Ocuphire Pharma. "If approved, oral APX3330 has the potential to address the high unmet need for early intervention for progressive vision-threatening diabetic eye disease, including diabetic retinopathy and diabetic macular edema. The timing is ideal as we continue to advance our fully enrolled clinical program investigating APX3330 in DR/DME where we have reported interim masked safety results at multiple medical meetings throughout this year demonstrating a consistent and favorable safety profile for a first-in-class oral treatment option. Top-line results from the Phase 2b ZETA-1 trial are expected in the second half of 2022." U.S. Patent No. 11,351,130 has claims directed to methods of treatment using APX3330, which makes it eligible for listing in the U.S. FDA Orange Book. It was issued on June 7, 2022 and has a term that expires in year 2038. Claims in this patent include methods of treating inflammation and chronic pain in a subject suffering from diabetes. Ocuphire also announced the publication of a preclinical study outlining the pivotal role of NFkB in Ref-1 inhibition in a pancreatic ductal adenocarcinoma cell model with a Kras genotype and offers evidence of anti-inflammatory benefits of APX3330 in PDAC.

09:05 EDT EnWave sells EU-GMP 10kW REV machine to pharmaceutical cannabis cultivator - EnWave Corporation announced that it has received a purchase order for an EU-GMP 10kW Radiant Energy Vacuum dehydration machine from an unnamed pharmaceutical cannabis company. The machine will be used to dry cannabis for medical consumption and for the creation of a wide range of derivative products. These products will be distributed into the European Union and legal worldwide markets. The facility is located in a region with optimal climates for pharmaceutical cannabis cultivation. Using a combination of natural agricultural methods, automated processes, and scientific precision, the cultivator is aiming to achieve the highest standards by improving patients' lives and revolutionising modern medicine with an incredible range of applications.

09:02 EDT Appian names new Chief People Officer and VP of Industry Products and Solutions - Appian appointed two new executives to Appian's leadership team. Susan Charnaux has been named Chief People Officer. Sanat Joshi joined as Senior VP of Industry Products and Solutions. Charnaux has more than 20 years of experience in professional services and human capital, including senior roles at Accenture and McKinsey & Company. Joshi has more than 30 years of experience in enterprise technology. He was most recently General Manager of Technology and Cross-Industry Solutions at Amazon Web Services. Prior to that, he led Oracle's industry strategy and go-to-market programs for Manufacturing and Automotive industries.

08:56 EDT Williams reaches final investment decision for LEG - Williams announced that it has reached a final investment decision on its clean energy project, the Louisiana Energy Gateway, or LEG, which will gather 1.8 Bcf/d of natural gas produced in the Haynesville basin for delivery to premium markets, including Transco, industrial markets and growing LNG export demand along the Gulf Coast. Williams intends to create opportunities to pursue additional market access projects as well as develop carbon capture and storage infrastructure that will further decarbonize the natural gas value chain. The project is expected to go into service in late 2024.

08:52 EDT Eco Material Technologies announces agreement with Georgia Power - Eco Material Technologies announced an agreement with Georgia Power to harvest millions of tons of landfilled ash from Plant Bowen, one of the largest coal-fired power plants in North America. Under the agreement, Eco Material will harvest approximately 600,000 tons of landfilled ash per year from the plant in Cartersville, Ga. The effort will remove and beneficially use more than 9M tons. There is also the potential to expand operations to a second location and double annual production to over 1M tons. The ash from Plant Bowen will be used in concrete blends to repair and construct bridges, roads, and buildings in Georgia as well as throughout the Southeast. Georgia Power is the largest electric subsidiary of Southern Company.

08:48 EDT CollPlant advances 3D bioprinted breast implants into porcine study - CollPlant initiated a study in large animals for its 3D bioprinted regenerative breast implant program, addressing the $2.8B global breast implant market. Immediately following the conclusion of this study, CollPlant plans to launch a second study with human size implants that mimic commercial products. CollPlant's bioprinted regenerative implants aim to overcome the challenges of existing breast procedures that use silicone implants or autologous fat transfer. CollPlant's regenerative breast implants are comprised of the company's proprietary plant-derived rhCollagen. The printed implant is intended to degrade over time while promoting natural tissue regeneration and integration with host tissue. 3D bioprinting technology enables scalable production of precise and repeatable constructs, which can be customized to the individual anatomy of patients. The company launched a large animal study that involves the implantation of reduced-size 3D bioprinted implants in a clinically relevant porcine animal model, which is planned to be concluded within six months. The study will also serve as the basis for the design of a pivotal large study with human size implants.

08:44 EDT Bed Bath & Beyond says aware of interest in BuyBuy Baby - Comments taken from Q1 earnings conference call.

08:40 EDT SciSparc completes the development of drug candidate SCI-110 - SciSparc (SPRC) announced that it has successfully completed the development of its top-tier drug candidate SCI-110 to be used in its upcoming multinational, multicenter, Phase IIb study for Tourette Syndrome, TS. The Company recently announced that it has received ethics committee approvals from Hannover Medical School in Hannover, Germany, and the Tel Aviv Sourasky Medical Center, in Tel Aviv, Israel. SCI-110 is developed and manufactured by Procaps Group (PROC). "Completing the development of our unique drug candidate SCI-110 for the upcoming Phase IIb trial is another significant milestone for the Company, making SciSparc well positioned to introduce an impactful treatment for TS patients that have very limited treatment options today," commented Oz Adler, SciSparc's Chief Executive Officer. "Our singular objective in developing SCI-110 is to develop a safe and effective treatment for this devastating, unmet medical need as soon as possible; and this milestone brings us one step closer." The objective of this Phase IIb randomized, multi-national, multi-center, double-blind, placebo controlled cross-over study is to evaluate the efficacy, safety and tolerability of SciSparc's proprietary drug candidate SCI-110 in adult patients using oral treatment daily. The primary efficacy objective of the study will be to assess tic severity change using Yale Global Tic Severity Scale as a continuous endpoint at week 12 and week 26 of the double-blind phase compared to baseline.

08:38 EDT JetBlue issues open letter to Spirit shareholders regarding Frontier deal - JetBlue (JBLU) issued an open letter to shareholders of Spirit (SAVE). The letter said, "Tomorrow, Spirit shareholders have YOUR chance to help assure you receive the most value for your Spirit shares by voting AGAINST the Frontier (ULCC) transaction. If you want more value and more certainty, sooner, your choice is clear. By voting AGAINST the Frontier transaction you vote FOR: A superior all-cash price of at least $33.50 per Spirit share, a premium of 51% to the implied value of the Frontier transaction as of June 28, 2022; An accelerated payment of $2.50 per Spirit share - or 13% more than Frontier's prepayment; Greater regulatory commitments, including a larger reverse break-up fee of $400 million and a more significant divestiture commitment than Frontier, despite similar regulatory profiles; and A ticking fee - a monthly prepayment of $0.10 per share from January 2023 until the deal is consummated or terminated. In fact, Spirit shareholders would receive more cash in the unlikely event a JetBlue deal is terminated ($4.30 per share assuming the ticking fee is paid in full) than they would receive if the Frontier transaction is consummated ($4.13 per share). Ultimately, however you assess the probability of regulatory approval of each transaction, you are always better off with the JetBlue transaction. As one of Spirit's top ten shareholders said, "We firmly believe that if, as shareholders, we must wait for a transaction to be consummated following a lengthy regulatory process, we are much better off waiting alongside JetBlue, which is willing to compensate us along the way. The Board's self-serving actions and failure to accept JetBlue's $33.50 per share offer is preventing shareholders from receiving superior value." Only by voting AGAINST the Frontier transaction can you assure that you will receive the benefits of our offer. The entrenched Spirit Board needs to know that you, their shareholders, want our better offer. Multiple Spirit directors have significant ties to Frontier's controlling shareholder, Bill Franke, resulting in a conflicted Spirit Board more focused on securing an inferior transaction with Frontier than maximizing value for its own shareholders. While negotiating for eight months with Frontier, Spirit's Board never seriously considered any alternatives, resulting in an original merger agreement with Frontier that was clearly suboptimal, with a low premium, no reverse break-up fee, and no divestiture commitment. Frontier has improved its offer twice since we launched our "vote no" campaign. The Spirit Board consistently ignored or refused to engage with JetBlue until faced with certain defeat on the original shareholder meeting date and then, in an attempt to avoid the widespread perception of its poor corporate governance, pretended to engage with JetBlue. The Spirit Board continues to forgo any engagement or good faith negotiation with JetBlue, publicly rejecting our latest proposal in less than a day without ever discussing the amended terms. Don't let the Spirit Board's allegiances to Frontier's controlling shareholder keep you from the most value creating opportunity. This is the time to make your voice heard and deliver a clear message to the entrenched Spirit Board that you want the superior JetBlue transaction."

08:37 EDT Middleby acquires automation solutions firm Proxaut, no terms - The Middleby Corporation announced the acquisition of Proxaut, a leading manufacturer of Auto Guided Vehicles AGVs for the food industry and industrial processing companies. The company is based in Italy near Bologna with approximately $15M in annual sales. "We are leading the trend for Industry 4.0 in food processing. Our recent strategic investments in automation are coming to fruition, as we see order demands for this technology," said Tim FitzGerald, Middleby CEO. "Middleby's investments in automation and integrated full line solutions are driving efficiencies and operating benefits for our food processing customers. These proven automation solutions reduce operator efforts and labor needs while increasing production, optimizing space, and streamlining loading between machines."

08:36 EDT Commvault's data management included on Oracle Cloud - Commvault (CVLT) has expanded its strategic partnership with Oracle (ORCL) to include Metallic DMaaS on Oracle Cloud. Metallic's services will be offered on Oracle Cloud Infrastructure and available in all commercial OCI regions globally. Metallic DMaaS aims to help protect data from corruption, unauthorized access, and other threats across vital sectors of business.

08:35 EDT AST SpaceMobile updates BlueWalker 3 launch timing for early to mid-September - AST SpaceMobile provided revised timing guidance on the launch of its BlueWalker 3 test satellite from Cape Canaveral, FL. AST SpaceMobile was notified by SpaceX, its launch provider, of an updated launch window for early to mid-September, from the previously announced window targeting the week of August 15 . There has been no change to BlueWalker 3 satellite preparations and the AST SpaceMobile team remains on schedule. The actual launch date remains subject to change and is contingent on a number of factors including, but not limited to, final testing, final integration, ground transport, timely readiness of the launch vehicle and other unknowns including, but not limited to, weather conditions or technical problems. "We look forward to providing regular updates as BlueWalker 3 completes its journey to Cape Canaveral," said Scott Wisniewski, AST SpaceMobile Chief Strategy Officer. "We also plan to provide further information on options for the public to view the launch, either in person or online."

08:32 EDT Triumph Group awarded contract from Mammoth Freighters - Triumph Group's Interiors business was awarded a contract from Mammoth Freighters for composite air distribution ducts on the Boeing 777 Passenger to Freighter conversions. Triumph Interiors will provide manufacturing and engineering support services for the Mammoth Freighters' re-designed air distribution ducting system in the cargo compartment.

08:32 EDT HTG Molecular announces peer reviewed journal article featuring HTP - HTG Molecular Diagnostics announced the customer publication of a peer reviewed journal article featuring the HTG Transcriptome Panel, HTP, less than one year after the breakthrough product's commercial release. The article, published in Frontiers in Medicine by one of several participants in the Company's HTP Early Adopter Program, applied the comprehensive HTP to query 19,398 mRNA targets in an effort to advance the understanding of how best to treat bladder cancer patients who do not fall into categories identified by routine tissue staining. According to study authors from University Hospital Frankfurt, Germany, a two-sided classification system based on CK5/6 and GATA3 expression using immunohistochemistry may not sufficiently reflect the heterogeneity of bladder cancer to make treatment decisions. Especially as it relates to the group of IHC-double negative cases, further analysis using the HTP for mRNA expression profiling was able to assist in identifying multiple molecular and histological subtypes, which has important implications for therapy selection in this heterogeneous group.

08:28 EDT Poet announces availability of 400G FR4, 800G Receive Optical Engines - POET Technologies announced the availability of its 400G FR4 and 800G Receive Optical Engines based on the POET Optical Interposer, a unique hybrid integration photonics packaging platform. "We are excited to announce the completion of design, verification testing, and availability of pre-production parts for customers to take advantage of our highly integrated optical engines to build 400G FR4 and 800G transceivers," said Vivek Rajgarhia, President of POET Technologies. "Our small form factor and easy-to-integrate optical engine enables cost-effective and scalable solutions for cloud data centers. Customers can integrate a single receive engine or dual engines in a QSFP-DD or OSFP pluggable transceiver form factor to achieve a 400GBASE-FR4 or 800G solution. The shipping of 400G receive samples marks a significant milestone for the Company, as we continue to commercialize multiple products and align them with the needs of customers."

08:27 EDT GoDaddy acquires Dan.com, terms not disclosed - The company states: "We are thrilled to share that GoDaddy entered into a definitive agreement to acquire Dan.com, a company on a mission to "to be a catalyst of innovation in the domain industry and make domain trading accessible to all." The Dan.com mission aligns well with GoDaddy's mission to empower entrepreneurs and make opportunity more inclusive for all. We believe this deal provides great opportunities for both GoDaddy and Dan.com customers with the integration of Dan.com's automation and lease to own options adding momentum to GoDaddy's goal of offering domain investors an integrated experience within a best-in-class marketplace empowered by sage guidance, cutting-edge data science and the world's premier brokerage team. With more than 84 million domains under management, GoDaddy intends for this acquisition to support continuing profitable revenue growth in our domains business. Terms of the deal were not disclosed."

08:24 EDT Bed Bath & Beyond sees Q2 QTD comp sales in negative 20% range - Says expects improvement in second half compared to the first half based on inventory optimization, including incremental clearance activity. Sees lower SG&A dollars vs. last year reflecting actions to align cost structure to sales. Sees FY22 capital expenditures $300M. Says assumes depreciation and amortization of $260M. Says strategy committee is actively assessing value potential of buybuy Baby. Says results are not up to expectations. Says facing difficult macro environment. Comments and guidance taken from Q1 investor presentation slides.

08:22 EDT Canadian National to invest $65M in Mississippi in 2022 - CN announced plans to invest approximately $65M in Mississippi in 2022. This includes investments in technology, capacity, rolling stock units and company-wide decarbonization initiatives, as well as network improvements. These investments will power sustainable growth and ensure the continued safe movement of goods in Mississippi and everywhere on CN's transcontinental network. Maintenance program highlights include: Replacing approximately 5 miles of rail; Installing approximately 130,000 new railroad ties; Rebuilding 14 road crossing surfaces; and Maintenance work on bridges, culverts, signal systems, and other track infrastructure.

08:21 EDT NV5 Global awarded $7M wastewater recycling project - NV5 Global announced that the City of Oceanside, California has selected NV5 for an approximately $7M contract to provide owner consultant services for a wastewater reclamation and recycling project. The project is part of the City's program to decommission the aging La Salina Water Treatment Plant and convey all wastewater flows to the San Luis Rey Wastewater Reclamation Facility for the production of recycled water to support the City's innovative indirect potable reuse initiative. The three-year project is expected to be completed in December 2025. "The importance of water conservation continues to grow as droughts become more frequent and severe, and NV5's leadership in sustainable infrastructure positions us to contribute to these water infrastructure initiatives," said Dickerson Wright, PE, Chairman and CEO of NV5. "NV5 has provided engineering and support services to the City of Oceanside for 14 years, and we look forward to continuing our relationship with the City on this essential water conservation project."

08:20 EDT Donegal Group appoints Spnic as SVP of Personal Lines - Donegal Insurance Group announced that David Sponic, CPCU, CIC, has been named Senior Vice President, SVP, of Personal Lines. Sponic succeeds longtime SVP of Personal Lines Jeff Jacobsen, who will transition into an advisory role leading up to his retirement in early 2023. Sponic previously led Donegal's Personal Lines Marietta Marketing and Home Office Underwriting Operations.

08:18 EDT Beam awarded Sate of California contract to supply EV ARC EV charging systems - Beam Global announced that the State of California has awarded contract #1-22-61-16 to supply EV ARC sustainable EV charging systems through the Department of General Services, DGS, to Beam Global. California state, local and municipal government entities, and government entities in other U.S. states, can purchase Beam products at the California negotiated price, without having to go through a lengthy procurement or technology review process. The award is effective June 24, 2022 through June 23, 2025 and is eligible for renewal through June 23, 2027. "This new contract with California is at once a powerful validation of our products which the state has been using for many years and also a strong indication of California's commitment to electrifying transportation and using rapidly deployed, sustainable and robust charging infrastructure products that are made in the U.S. to fuel this new generation of vehicles," said Beam Global CEO Desmond Wheatley. "Consumers, companies and governments are adopting EVs at a faster rate than ever and yet we are still just at the beginning of this massive shift. The need for EV charging infrastructure is becoming greater and more urgent every day. Our ability to rapidly scale and deploy EV chargers without construction or electrical work and without utility bills, grid capacity constraints or vulnerability to black-outs, is becoming increasingly recognized as vital to the success of this evolution. We are busier than ever but we're planning on getting a lot more busy."

08:16 EDT NeuBase Therapeutics promotes Mann to President - NeuBase Therapeutics announced the promotion of William Mann, Ph.D. to President of the Company, effective immediately. Dr. Mann will also continue to serve as NeuBase's Chief Operating Officer. "Since joining NeuBase as our Chief Operating Officer in July 2020, Dr. Mann has played an integral role in the advancement of the Company's PATrOL platform and pipeline of therapeutic programs to treat myotonic dystrophy type 1, Huntington's disease, and KRAS-driven cancers," said Dietrich A. Stephan, Ph.D., Founder, Chief Executive Officer, and Chairman of NeuBase.

08:09 EDT Vivos announces exclusive distribution agreement with GM Instruments - Vivos Therapeutics announced it has entered into an exclusive distribution agreement with GM Instruments for the distribution of GM Instruments' NR6 Rhinomanometer, the only FDA approved 4-phase rhinomanometer available in the U.S. used to calculate nasal airway resistance by measuring nasal flow and the pressure producing that flow. Under this new agreement, effectively immediately, Vivos becomes the exclusive U.S. and Canadian distributor of this specialized diagnostic equipment for evaluating nasal breathing and function in dental patients with sleep and breathing issues. The objective measurement of nasal breathing can be an essential data point in determining the appropriate breathing and sleep issue treatment pathway as well as a predictor of potential Continuous Positive Airway Pressure intolerance or other treatment failure. "With this new agreement, every U.S. or Canadian dentist who wishes to evaluate the breathing function of a patient will need to engage with Vivos for this diagnostic equipment. We expect this will provide Vivos an immediate new revenue stream as well as a substantial competitive advantage and opportunity to present Vivos' proprietary oral appliance technology to a wider audience," said Vivos Chairman and CEO, Kirk Huntsman.

08:08 EDT Bionano issued US patent for analysis of small nucleic acid fragments - Bionano Genomics announced that the United States Patent and Trademark Office issued US Patent No.11,359,244 on June 14, 2022. The patent, titled "CHARACTERIZATION OF MOLECULES IN NANOFLUIDICS" claims methods for the analysis of small nucleic acid fragments in nanochannel arrays, which Bionano has traditionally used to analyze ultra-high molecular weight DNA for the identification of structural variants as part of its Saphyr system. The methods claim the use of certain nanochannel arrays to detect and quantitate genetic abnormalities, including a DNA translocation, amplification, transversion, inversion, aneuploidy, polyploidy, monosomy, trisomy, trisomy 21, trisomy 13, trisomy 14, trisomy 15, trisomy 16, trisomy 18, trisomy 22, triploidy, tetraploidy, and sex chromosome aneuploidy. Bionano believes that the methods disclosed in the '244 patent may one day support the commercialization of assays directed to non-invasive prenatal testing in maternal fetal medicine or ctDNA in oncology. "At Bionano, we remain committed to expanding the utility of our nanochannel arrays and creating a robust patent portfolio that protects those applications. This patent is an exciting example of technology that may prove useful for creating new applications in important areas of medicine," commented Erik Holmlin, PhD, president and chief executive officer of Bionano Genomics.

08:06 EDT Global Blood Therapeutics initiates Phase 2/3 clinical trial of GBT601 - Global Blood Therapeutics announced that it initiated the Phase 2 portion of a planned Phase 2/3 trial of GBT021601, the company's investigational next-generation sickle hemoglobin polymerization inhibitor. The study is a randomized, multicenter Phase 2/3 clinical trial evaluating the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of GBT601. The study is planned to include sites in Africa, Europe, the Middle East, South America, and the United States, including several sites that are expected to begin enrolling patients in the near term. The Phase 2 portion of the study will evaluate the safety, tolerability, and efficacy of GBT601 and enroll up to 60 patients with SCD who are 18 to 65 years of age. The primary outcome measure is the number of participants with a change from baseline in Hb through Week 12. Secondary outcomes measures include assessments of PK and PD, as well as an assessment of the relationship between GBT601 and measures of anemia and hemolysis. Following the selection of the optimal safe and effective dose of GBT601 from the Phase 2 portion of the study, the Phase 3 portion will assess the efficacy and safety of the selected optimal dose compared to placebo in adult and pediatric SCD patients for 48 weeks.

08:04 EDT BioLineRx enters co-development agreement with GenFleet for Motixafortide - M.S.Q. Ventures is pleased to announce that its client, BioLineRx, has successfully entered into a co-development agreement with GenFleet Therapeutics for the development of Motixafortide in pancreatic ductal adenocarcinoma. Under the terms of the agreement, GenFleet will design and execute a randomized Phase 2b clinical trial that will enroll approximately 200 first-line metastatic PDAC patients in China. This randomized controlled study will aim to evaluate the superiority of Motixafortide in combination with an anti-PD-1 and chemotherapy compared to chemotherapy alone, the current standard of care.

08:02 EDT ViaSat's Mark Dankberg to resume Chairman & CEO roles - Viasat announced that, effective July 1, Mark Dankberg, Viasat's co-founder and executive chairman, will resume the roles of chairman and CEO, while current President and CEO Rick Baldridge will assume a newly created vice chairman position. Baldridge will focus on the remaining steps to closing the Inmarsat acquisition, and the organizational integration planning and execution strategy to position the combined companies to achieve the financial and operational objectives underpinning the transaction - including cost, capital, and revenue synergies already identified. The organization change follows Viasat's recent overwhelming shareholder approval for the acquisition of Inmarsat. Baldridge will also continue to lead Viasat's evaluations of strategic initiatives and certain ongoing organizational initiatives.

07:53 EDT General Mills up 2.4% in pre-market at $71.96 after Q4 beat, dividend hike

07:48 EDT FedEx introduces 2025 targets at investor meeting - FedEx is hosting an investors meeting where president and CEO Raj Subramaniam and the FedEx leadership team will present a strategic plan. FedEx will also outline its fiscal 2025 financial targets. FedEx is targeting to deliver 18%-22% annualized TSR through fiscal 2025 based upon these balanced financial goals for fiscal 2025: 4%-6% compound annual revenue growth through fiscal 2025; 10% adjusted consolidated operating margin; 11%-12% FedEx Ground adjusted operating margin; 8%-9% FedEx Express adjusted operating margin 20%-22% FedEx Freight adjusted operating margin; adjusted dividend payout ratio of at least 25%; ratio of capital expenditures to revenue equal to or less than 6.5% and an increase of 200 basis points in FedEx's return on invested capital compared to fiscal 2022. The company also expects fiscal 2025 adjusted consolidated operating income improvement of $3B-$4.5B compared to fiscal 2022 adjusted consolidated operating income and compound annual growth rate for adjusted EPS of 14%-19% through fiscal 2025.

07:47 EDT Jushi Holdings debuts line of concentrate products - Jushi Holdings debuted its first line of concentrates made using hydrocarbon extraction by its brand The Lab. The Lab Live Resin is the second of several single-source concentrate product lines to be launched by Jushi. Last month, the Company launched its first line of solventless live rosin extracts. Initially, Jushi will exclusively carry The Lab Live Resin 500mg full-spectrum 0.5 gram 510 cartridges at Beyond Hello retail locations in Pennsylvania. The Company plans to roll out its hydrocarbon-extracted line at partner dispensaries across the Commonwealth in the coming months, as well as in additional states such as Massachusetts, Virginia and Nevada. The Company also plans to launch a 300mg rechargeable, all-in-one 0.3g vape and a variety of 1 gram jarred cured concentrates in the coming months, pending regulatory approval.

07:43 EDT Mindset Pharma announces development of novel intranasal formulation - Mindset Pharma announced that the Company has developed a novel, patent-pending, intranasal platform formulation technology expected to deliver improved central nervous system, CNS, penetration of first and subsequent generations of psychedelic medicines. Mindset's novel intranasal formulation technology leverages its platform technology, a common feature of several of Mindset's leading psychedelic drug candidates, altering the pharmacokinetics profile of the active pharmaceutical ingredient. The proof of concept of this novel formulation demonstrates improved CNS penetration compared to standard formulations of 5-MeO-DMT. Data also demonstrates increased CSF exposure relative to plasma in comparison to a standard formulation by a factor of approximately 3. "The intranasal formulation technology further enhances Mindset's portfolio of complementary scientific assets. Now, the Company has a leading portfolio of next generation NCEs, patent pending processes to synthesize first generation compounds efficiently and cost-effectively, and a novel intranasal delivery system to improve the overall pharmacokinetic properties of first- and second-generation psychedelic drug candidates," commented James Lanthier, CEO of Mindset Pharma.

07:40 EDT Bed Bath & Beyond drops 16% to $5.50 after Q1 results miss estimates, CEO change

07:39 EDT SL Green Realty announces closing of 450 Park Avenue acquisition - SL Green Realty announced that it closed on the previously announced acquisition of 450 Park Avenue in a newly formed joint venture. The ownership group consists of institutional investors from South Korea and Israel. SL Green retained a 25.1%i nterest in the property and will oversee leasing and management of the property on behalf of the partnership. "The international demand to partner with us on the acquisition of 450 Park Avenue demonstrates that New York City continues to maintain its position as one of the most sought-after real estate markets and a safe haven for long-term capital deployment," said Harrison Sitomer, Chief Investment Officer of SL Green. "The acquisition of this world-class asset is a meaningful enhancement to our growing investment management platform." The partnership financed the acquisition with a $267.0M senior mortgage financing provided by a bank group led by Wells Fargo Bank, N.A.

07:37 EDT Galera Therapeutics announces results from Phase 1 stage of GRECO-1 trial - Galera Therapeutics announced results from the open-label Phase 1 stage of the GRECO-1 trial of rucosopasem in combination with stereotactic body radiation therapy, SBRT, in patients with centrally located or large non-small cell lung cancer, NSCLC. Enrollment is ongoing in the randomized, double-blinded, placebo-controlled Phase 2 stage of the trial, with completion of enrollment anticipated in the second half of 2023. Key findings in this group of seven patients include: Rucosopasem in combination with SBRT appeared well tolerated. In-field partial responses or stable disease were seen in six of the seven patients at six months follow-up, including target tumor reductions in five patients of 61%, 58%, 33%, 29% and 27% from baseline. Early evidence of protection of pulmonary function was observed compared to the literature. No Grade 2-4 declines in DLCO1 were seen in any of the seven patients receiving rucosopasem compared to a prospective trial evaluating pulmonary function after four to five fractions of lung SBRT, in which 7-12% of patients had Grade 2-4 decline in DLCO. GRECO-1 consists of two stages. The primary endpoint of this open-label Phase 1 stage was safety of 100 mg of rucosopasem administered intravenously over 15 minutes in combination with each of five SBRT treatments. Secondary endpoints include late toxicities through 12 months and anti-cancer efficacy through 24 months. Anti-cancer endpoints include overall and progression-free survival, as well as local tumor and distant metastasis control. The Phase 2 stage of GRECO-1 is a randomized, double-blinded, placebo-controlled evaluation in up to 66 patients with large and/or central NSCLC tumors. Patients are being randomized in a 1:1 ratio to receive either 100 mg of rucosopasem or placebo before each fraction of SBRT. The primary endpoint of the Phase 2 stage of the trial is in-field tumor response at six months post SBRT. Patients are also being followed for long-term anti-cancer endpoints and safety similar to the Phase 1 stage of the trial.

07:35 EDT Lilium engages Astronics for Lilium Jet's power distribution system - Lilium N.V. (LILM) has selected Astronics Corporation (ATRO) to design, develop, and build the Lilium Jet's electrical power distribution system. Astronics will be responsible for the secondary power distribution units, SPDUs, and charging power distribution units, CPDUs. Lilium Jets will each be equipped with two SPDUs and one CPDU. SPDUs are responsible for high voltage to low voltage conversion and for low voltage distribution and protection. The CPDU manages the battery charging operation, as well as providing additional and dissimilar sources for high voltage to low voltage power conversion and low voltage power distribution. Martin Schuebel, Senior Vice President Procurement at Lilium, said: "Astronics is our ideal partner for this very important component of our aircraft. It is our intention to collaborate with the best aerospace suppliers and leverage their expertise. Astronics' expertise is unique, and their collaborative approach makes them a perfect match for us. The partnership will also help pave the way for the coming industrial ramp-up."

07:34 EDT Bed Bath & Beyond reports Q1 adjusted gross margin 23.8% - GAAP Gross Margin was 23.9% for the quarter. Excluding special items, Adjusted Gross Margin was 23.8%, inclusive of transient costs associated with a 620 basis point negative impact from markdown inventory reserves and 220 basis point negative impact from supply chain-related port fees compared to last year. Excluding the aforementioned 840 basis points of transient costs, Q1 Adjusted Gross Margin was 32.2%. The company is proactively working with suppliers to adjust future inventory receipts and accelerating markdowns in order to right-size inventory levels commensurate with the declining sales trends.

07:32 EDT Bed Bath & Beyond sees sequential SSS recovery in 2H22 - At this time, the company is providing the following outlook parameters for Fiscal 2022: Sequential Comparable Sales recovery to occur in the second half of Fiscal 2022 versus the first half of Fiscal 2022 driven by inventory optimization plans, including incremental clearance activity. Adjusted SG&A expense for Fiscal 2022 below last year, reflecting aggressive actions to align cost structure to sales. Capital Expenditures of approximately $300M, from $400M previusly for Fiscal 2022, reflecting a minimum reduction of $100M.

07:28 EDT Bed Bath & Beyond announces Sue Gove appointed Interim CEO

07:21 EDT Surface Oncology appoints Brunn to board of directors - Surface Oncology (SURF) announced that Carsten Brunn, Ph.D., will join the company's board of directors. Dr. Brunn brings more than 25 years of senior leadership experience spanning multiple biotech and pharmaceutical companies. Dr. Brunn is president and chief executive officer at Selecta Biosciences (SELB), a clinical stage precision immune tolerance platform company.

07:18 EDT CynergisTek announces expiration of excluded party 'go-shop' period - CynergisTek announces the expiration of the Excluded Party "go-shop" period set forth in the previously announced merger agreement with Clearwater Compliance in an all cash transaction that values CynergisTek at approximately $17.7M. All capitalized but undefined terms used herein have the meanings given in the Merger Agreement. As previously announced, prior to the expiration of the initial "go-shop" period under the Merger Agreement, CynergisTek received an Acquisition Proposal from a potential strategic buyer who had been contacted by CynergisTek's financial advisors , and thereafter CynergisTek has been engaged in negotiations with the potential strategic buyer regarding the terms and conditions of the Go-Shop Proposal. As previously announced, on June 22 , the CynergisTek Board of Directors determined, in good faith after consultation with its outside financial advisor and legal counsel, that the Go-Shop Proposal would reasonably be expected to lead to a Superior Proposal, thereby making the potential strategic buyer an Excluded Party under the terms of the Merger Agreement. After continued negotiation with the potential strategic buyer prior to the expiration of the Excluded Party "go-shop" period under the Merger Agreement, at this time the Board has not determined that the Go-Shop Proposal constitutes a Superior Proposal, and there can be no assurances that a transaction will result from the Go-Shop Proposal or that any alternative transaction will be entered into or consummated.

07:16 EDT XPO Logistics expands use of sustainable biofuel at Tour de France - XPO Logistics will take to the road in July for the 42nd year as the official transport partner of the Tour de France. When the winner of the legendary cycling competition is declared at the Champs-Elysees in Paris, an XPO team of 58 drivers will have transported more than 570 tons of goods over 3,328 kilometers in 42 trucks - and 18 of those trucks will be fueled by biodegradable hydrotreated vegetable oil, HVO. Luis Gomez, president of XPO Logistics - Europe, said, "We're delighted to provide the Tour de France with an unprecedented level of support this year, while expanding the scope of our eco-friendly operations. It is a privilege to partner with one of the greatest competitions in the world for more than four decades."

07:14 EDT Barnes & Noble Education sees FY23 adjusted EBITDA $30M-$40M - The company said, "For fiscal year 2023, the Company expects consolidated non-GAAP Adjusted EBITDA to be between $30 million to $40 million. The Company expects significant improvement in its Retail business being driven by new First Day Complete implementations, growth within its general merchandise business and new business wins. The challenges within its wholesale business, including constrained used book inventory and higher inflationary pressures on wages and freight, are expected to persist. DSS non-GAAP Adjusted EBITDA is expected to be near fiscal year 2022 levels as revenue growth is offset by investments in product enhancements."

07:09 EDT Synlogic appoints Brendan St. Amant as General Counsel, Corporate Secretary - Synlogic announced the appointment of Brendan St. Amant as General Counsel and Corporate Secretary effective July 1, 2022. Brendan St. Amant joined Synlogic in 2021 as Vice President, Head of Legal.

07:06 EDT Agenus announces expanded data from Phase 1b study of botensilimab, balstilimab - Agenus announced expanded data from the Phase 1b study of botensilimab and balstilimab in patients with microsatellite stable colorectal cancer, MSS CRC. The data demonstrate that the combination offers strong durability and superior efficacy than what has been reported in separate trials for standard of care and other investigational therapies in 2L+ MSS CRC. Study Highlights: A total of 41 evaluable patients with metastatic MSS CRC received either 1 or 2 mg/kg botensilimab Q6W, and 3 mg/kg balstilimab Q2W. Patients were heavily pre-treated, with a median of 4 prior lines of therapy, and 34% had received prior immunotherapy. Objective responses: 24% overall response rate; 73% disease control rate; 50% objective responses with greater than 50% tumor reduction. Durability: 80% objective responses ongoing at data cut-off; 30% objective responses exceeding 1 year, Patient Sub-Populations: Objective responses in 5 patients with RAS mutations for a 24% overall response rate and 81% disease control rate in this population; other PD-1 combinations in separate trials have reported only rare responses in this population; Responses observed in patients with metastases historically resistant to immunotherapy, including patients with malignant pleural effusions, soft tissue, peritoneal, retroperitoneal, and bone metastases. Tolerability: Botensilimab was well tolerated, with no grade 4/5 treatment-related adverse events; Rates of gastrointestinal and skin toxicities were comparable to those reported with first-generation CTLA-4 inhibitors

07:04 EDT Nuwellis announces first patient enrolled in REVERSE-HF study - Nuwellis announced the first patient has been enrolled in the company's pivotal REVERSE-HF clinical study. REVERSE-HF will evaluate the clinical outcomes and economic value of its Aquadex ultrafiltration therapy in comparison to intravenous, IV, diuretics for the treatment of fluid overload in patients with worsening heart failure. REVERSE-HF is a multicenter, open-label, randomized controlled trial that will be conducted across the United States. The study is led by Sean Pinney, M.D. and Maria V. DeVita, M.D. "The first patient enrolled in REVERSE-HF marks an exciting milestone in this study," said Nestor Jaramillo, Jr., President and CEO of Nuwellis. "As a company, we are committed to the ultimate goal of making Aquadex therapy the standard of care for fluid management in heart failure patients that are resistant to diuretics. In talking to medical societies, Nuwellis has been told that REVERSE-HF will produce the necessary evidence these societies need to have ultrafiltration included within their medical guidelines. We look forward to forthcoming clinical publications that support our belief that REVERSE-HF will be a very positive study." The primary effectiveness endpoint of REVERSE-HF will evaluate mortality and heart failure events within 30 days and 90 days as a comparison between Aquadex therapy and IV loop diuretics.

07:02 EDT Full Truck Alliance apps resume new user registration - Full Truck Alliance's Yunmanman and Huochebang apps resumed new user registration. The Cybersecurity Review Office of the Cyberspace Administration of China initiated a cybersecurity review of FTA's Yunmanman and Huochebang apps last July. FTA has fully cooperated with the CRO in the cybersecurity review and has taken comprehensive measures to address issues identified during the process. The CRO informed FTA that its Yunmanman and Huochebang apps may resume new user registration.

06:48 EDT Eli Lilly to supply additional 150,000 doses of bebtelovimab to U.S. for $275M - Eli Lilly announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately $275M. The existing U.S. government supply of bebtelovimab, including the new purchase, is expected to meet present demand through late August. Bebtelovimab continues to maintain neutralization activity against the most common, and fastest growing, Omicron variants in the United States, in addition to all known variants of interest and concern. Delivery of doses will begin immediately and complete no later than August 5. The 2022 estimated financial impact of this agreement is approximately $275M of revenue and approximately 8c of EPS. An option for an additional 350,000 doses to be exercised no later than September 14, 2022 will remain in the agreement.

06:41 EDT MSC Industrial expects double-digit average daily sales growth in Q4 - Kristen Actis-Grande, executive VP and CFO, added, "Double-digit sales growth, gross margin execution and productivity all combined to expand adjusted operating margin by 200 basis in the fiscal third quarter with an adjusted incremental margin in the thirties. Looking to the fiscal fourth quarter, we expect double-digit average daily sales growth to continue and to finish the year in the top scenario of our fiscal 2022 annual framework."

06:05 EDT Telus to acquire shares of Telus International for $66M - Telus' indirect, wholly-owned subsidiary has entered into a purchase agreement with an entity affiliated with Baring Private Equity Asia - BPEA - relating to the acquisition by Telus of 3,000,000 multiple voting shares in the capital of Telus International from BPEA. The purchase of these shares is being made pursuant to the private agreement exemption set forth in section 4.2 of National Instrument 62-104. The purchased shares represent approximately 1.5% of the outstanding multiple voting shares of Telus International and approximately 1.1% of all outstanding shares. The shares are being acquired for a purchase price of $22.00 per purchased share, representing aggregate consideration of $66M. After the purchase, Telus will hold an aggregate of 149,504,019 multiple voting shares and no subordinate voting shares, representing approximately 56.17% of the outstanding shares of Telus International, 74.78% of the outstanding multiple voting shares of Telus International and 72.38% of the outstanding voting rights of Telus International. Telus currently has no other plans or intentions that relate to its investment in TELUS International. The headquarters and principal executive offices of Telus International are located in Vancouver, Canada.

05:31 EDT Nordic issues shareholder letter regarding delivery of two new vessels - The letter said: "On May 13, 2022, we took delivery of the first of two recent suezmax tanker newbuildings from Samsung shipyard in South Korea. The vessel, which can carry one million barrels of oil, was named Nordic Harrier. We are always pleased to do business with South Korean shipbuilders, since their vessels are first-rate and always delivered on schedule. The second newbuilding, to be named Nordic Hunter, will be delivered in a few days and will also commence a contract for six years to ASYAD Shipping Company of the Sultanate of Oman. The contract begins promptly upon delivery from the yard, immediately producing earnings and cash-flow and further strengthening the NAT position in the crucial Middle East region. Both newbuildings mentioned in this message are fully financed via our partner Ocean Yield, a company controlled by Kohlberg Kravis Roberts (KKR), which is headquartered in the US. The NAT fleet consists of 20 vessels, all of them suezmax tankers, thus ensuring us both the reliability and flexibility of a uniform operation."

05:23 EDT Nio issues statement in response to short seller report - Nio issued the following statement in response to allegations made in a report by Grizzly Research, a short seller. "The report is without merit and contains numerous errors, unsupported speculations and misleading conclusions and interpretations regarding information relating to the Company. The Company's board of directors, including the audit committee, is reviewing the allegations and considering the appropriate course of action to protect the interests of all shareholders. The Company will make additional disclosures in due course consistent with the requirements of applicable rules and regulations of the Securities and Exchange Commission, the New York Stock Exchange, The Stock Exchange of Hong Kong Limited (the "SEHK") and the Singapore Exchange Securities Trading Limited (the "SGX-ST"). The Company emphasizes its continued and unwavering commitment to maintaining high standards of corporate governance and internal control, as well as transparent and timely disclosure in compliance with applicable rules and regulations."

05:20 EDT Veon reports 5M22 revenue up 1.3% - Veon will disclose key financial highlights for the first five months of 2022, or 5M22, at the annual general meeting of shareholders being held. Veon Group 5M22 consolidated revenue, is in positive territory, up by 1.3% in reported currency, and by 8.7% year-over-year in local currency terms, with six of the eight countries reporting double-digit local currency revenue growth for the period. Group CEO Kaan Terzioglu commented: "Our digital operator strategy is delivering solid results, enabled by growing 4G penetration. VEON Group's topline growth was an encouraging 8.7% YoY in local currency terms, driven by solid performance in our operations, despite the particularly challenging circumstances. Building on an expanding portfolio of services and with a constant focus on customer experience, our operations are growing their subscriber base, improving their user engagement, reducing churn, increasing their ARPU levels and gaining market share. I am proud of the work done by our teams, and would like to thank our Board and shareholders for their support."

05:12 EDT Freyr Battery sanctions construction of Giga Arctic - Freyr Battery announced that the company's board of directors has approved the expansion of the planned Giga Arctic project under development in Mo i Rana, Norway, to an annual nameplate capacity of 29 GWh. Freyr's board of directors has also approved the construction of Giga Arctic. The approval follows substantial completion of plant engineering; the establishment of procurement frameworks with raw material and capital equipment suppliers; and the announcements of conditional offtake agreements totaling more than 125 GWh from the planned start of production in 1H-2024 through 2030. Groundworks at the site are advanced and the company has recently started casting foundation structures. The board's decision coincides with the announcement of a letter of intent indicating loans and/or guarantees of up to EUR 400M from Eksfin, Norway's export credit agency, or ECA, and the recently announced National Battery Strategy by the Norwegian Government, which outlines meaningful governmental support for the developing battery industry in Norway. the Norwegian Government announced the key elements of its National Battery Strategy at Freyr's facilities in Mo i Rana, Norway. With the expected financial backing catalyzed by this strategy and support from other European governmental entities, Freyr has identified over $1.6B of potential debt financing support to fund development of Giga Arctic, including: a letter of intent received from Eksfin indicating loans and/or guarantees of up to EUR 400M; anticipated loan guarantees exceeding $800M from ECAs of three OECD countries based on capital equipment order frameworks for Giga Arctic from the same plant equipment suppliers to Freyr's Customer Qualification Plant; indications of support received from multilateral development finance institutions, which include potential loans of $300M from the European Investment Bank, or EIB, and $50M to $100M from the Nordic Investment Bank, or NIB, respectively and targeted project financing from a consortium of commercial banks led by initial mandated lead arrangers Societe Generale and DNB, which are now formally launching the project financing process. In addition, Freyr had $523M of cash on its balance sheet as of March 31 and currently has multiple grant applications pending decision. The sanctioned Giga Arctic construction project includes eight production lines, a battery testing center, administrative facilities, and infrastructure at an estimated total capital cost of $1.7B. The updated cost relative to Freyr's initial business plan, which was finalized in February, is attributable to the following: a 150% increase in nameplate capacity on a chemistry equivalent basis to 29 GWh from the initial plan to construct two smaller Gigafactories in Mo i Rana1; technical modifications and enhancements to the plant and its products and inflationary pressures and supply chain challenges. Freyr has engineered and positioned Giga Arctic to have 50% lower estimated capital expenditures per installed GWh of capacity compared to plants currently in operation or under construction. The company also expects Giga Arctic to be the most operationally efficient battery plant in Europe, generating an anticipated 200% higher production per plant employee compared to estimated averages at conventional Lithium-Ion battery facilities. These expected efficiencies are aided by Freyr's recently announced long-term power purchase agreement, or PPA, with Statkraft. Giga Arctic is expected to benefit from 100% renewable energy at prices that Freyr estimates to be substantially below those of other battery producing regions, while using less energy in production through the 24M Technologies SemiSolid cell manufacturing process and platform. Freyr is also evaluating additional enhancements to the Giga Arctic development that include module and pack manufacturing, recycling and other applications which could add approximately $250M of additional capital expenditures. Management expects the above investments to generate highly accretive returns on capital for the project should the company move forward with these initiatives. In addition, the company continues to evaluate its proposed joint venture with Aleees for a Nordic LFP cathode materials manufacturing plant.